Melanoma
"Is the Survival of Melanoma Patients Receiving Polyvalent Melanoma Cell Vaccine Linked to the Human Leukocyte Antigen Phenotype of Patients?."
Published in Cancer Weekly, May 18th, 1998
According to the authors' abstract of an article published in Journal of Clinical Oncology, "Purpose: An allogeneic polyvalent melanoma cell vaccine (PMCV) has been shown to be efficacious in improving overall survival of patients with malignant melanoma in a Phase II clinical setting. The PMCV consists of three allogeneic melanoma cell lines. The objectives of the study were to determine (1) whether the survival of melanoma patients who received PMCV was related to the patient's human leukocyte antigen (HLA) class I phenotype matching the HLA class I phenotype of the PMCV, and (2) whether PMCV clinical efficacy was correlated to melanoma patients with a particular HLA...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (1998-05-18)
More Articles from Cancer Weekly
- Cancer Gene Therapy (Prostate)
Preclinical Model Demonstrates Safety of Suicide Gene Therapy - Cancer Immunotherapy
IL-2 or GM-CSF Secreting Neuroblastoma Cells Demonstrate Impaired Tumorigenicity - Vector Applications
Adenovirus Vectors Successfully Transduce Mobilized CD34+ Cells - Cancer Vaccines
Superantigen Soups Up Melanoma Vaccine - Nasopharyngeal Carcinoma
Dual EBV and HPV Infection May Affect Regulation of Cellular Proliferation - Stem Cell Transplantation
Allogeneic Nonmyeloablative Stem Cell Transplants May Replace Allogeneic BMT - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
